Precision Pan-Cancer Tumor Killing

About Atengen

Atengen’s novel therapeutic target is expressed specifically in tumor blood vessels of most types of solid tumors but not in the blood vessels of healthy organs. Our scientists have used innovative technologies to identify several drug candidates that not only suppress tumor growth by inhibiting new blood vessel growth, but also cause extensive tumor necrosis by killing existing tumor blood vessels. In targeting the tumor blood supply rather than the tumor cells themselves, we can kill solid tumors in a tissue agnostic manner, while still maintaining a high degree of specificity. This groundbreaking approach has the potential to revolutionize the treatment of solid tumors.

A strategy to kill solid tumors in a tissue-agnostic manner

Atengen is developing drugs that target a novel receptor found in the blood vessels of most solid tumors. We are developing a new generation of therapeutics designed to kill tumors by killing tumor blood vessels.

Atengen Blood Vessel Killing

Our Approach

We believe that our approach has several potential advantages compared to other solid tumor therapies that are currently available or in development.

specific target

Specific Target

Our target is highly specific; it is only found in tumor blood vessels.

Broad Target

Broad Target

At the same time, our target is very broad; it is present in the tumor blood vessels of most solid tumors.

blood vessel killing

Kills Tumor Blood Vessels

Our approach disrupts new tumor blood vessel growth that is mediated by multiple different angiogenic factors and results in the death of existing tumor blood vessels.


Suppress and Kill Solid Tumors

Our approach both suppresses tumor growth and kills existing tumors.


Less Susceptible to Mutagenesis

Since we are not targeting cancer cells, our approach is less susceptible to mutagenesis.

Watch Our Video

Our Pipeline


Scientific Advisory Board


Napoleone Ferrara, MD


Dr. Ferrara is a Distinguished Professor at UCSD. He obtained his M.D. from the University of Catania and conducted post-doctoral research at UCSF. 


Yihai Cao, MD, PhD

Karolinska Institutet, Stockholm, Sweden

Dr. Cao is a Distinguished Professor of Vascular Biology at Karolinska Institute in Stockholm, Sweden. He received his Ph.D. from the Karolinska Institute and trained with Dr. Judah Folkman at Harvard.


Ernest Wright, PhD, FRS


Dr. Wright is a Distinguished Professor of Physiology and Medicine at UCLA. He received his Ph.D. at University of Sheffield and was trained at Harvard.


Jeremy Nathans, MD, PhD

Johns Hopkins University School of Medicine 

Dr. Nathans is a Howard Hughes Medical Institute Investigator and Professor at Johns Hopkins School of Medicine. He received his M.D. and Ph.D. degrees from Stanford University.


Steven McKnight, PhD

UT Southwestern

Dr. McKnight is a Distinguished Professor at UT Southwestern Medical Center. He received his Ph.D. from the University of Virginia and conducted post-doctoral research at the Carnegie Institute of Washington.

If you are interested in connecting with Atengen, please send us an email: moc.negneta%40ofni